Effectiveness of FF/UMEC/VI versus ICS/LABA in Patients with Uncontrolled Asthma Treated in Routine Clinical Practice (PERFORM): A Pragmatic Randomized Controlled Trial
Erika Penz, Stephen G Noorduyn, Alison C Moore, Hiroyuki Nagase, Jodie Crawford, Mary Woessner, Lydia Demetriou, Nicola Brown, David Slade, Gabriel Garcia, Alan P Baptist, John J Oppenheimer · 2026
Read Effectiveness of FF/UMEC/VI versus ICS/LABA in Patients with Uncontrolled Asthma Treated in Routine Clinical Practice (PERFORM): A Pragmatic Randomized Controlled Trial by Erika Penz, Stephen G Noorduyn, Alison C Moore, Hiroyuki Nagase, Jodie Crawford, Mary Woessner, Lydia Demetriou, Nicola Brown, David Slade, Gabriel Garcia, Alan P Baptist, John J Oppenheimer (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13159957.txt.
Description
Erika Penz and co-authors ran the PERFORM trial in 2026 on asthma that stays uncontrolled on standard inhalers. Guidelines step up care in stages, yet many patients still wheeze and flare. Triple therapy in one inhaler helped in strict trials, but those trials skim ideal patients.
PERFORM took the question into routine practice. Patients on dual therapy were randomized to switch to once-daily triple therapy or stay. Lung function, symptoms, and flares were tracked under real clinic habits. A pragmatic win here speaks louder to doctors than a lab-perfect one, since it mirrors the patients they actually see.
Catalog record
| CREATOR | Erika Penz, Stephen G Noorduyn, Alison C Moore, Hiroyuki Nagase, Jodie Crawford, Mary Woessner, Lydia Demetriou, Nicola Brown, David Slade, Gabriel Garcia, Alan P Baptist, John J Oppenheimer |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |